Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. (Q34376916)

1 August 2017

1 reference

title

Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. (English)

1 reference

1 August 2017

main subject

cardiovascular disease

1 reference

1 reference

Wojta J

1 reference

1 August 2017

Huber K

1 reference

1 August 2017

Christ G

series ordinal

1 reference

1 August 2017

Gulba D

series ordinal

1 reference

1 August 2017

publication date

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

103 Suppl 1

1 reference

1 August 2017

page(s)

S7-19

1 reference

Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Cell-associated plasminogen activation: regulation and physiological functions

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Dietary regulation of fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

The insulin resistance syndrome in smokers is related to smoking habits

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Lysis of Platelet‐rich Thrombi: The Role of PAI–1a

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Thrombolytic therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

A faster-acting and more potent form of tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

[Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

Plasminogen activator inhibitor in the blood of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2801%2900293-6

7 January 2021

10.1016/S0049-3848(01)00293-6

Identifiers

DOI

1 reference

1 August 2017

1 reference